743 results on '"Silvestris, N"'
Search Results
102. Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (pts) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now?
103. Mast Cells (MCs) Infiltration Affects Pancreatic Cancer (PC) Response To Gemcitabine Based Chemotherapy: In Vitro New Insights
104. Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: combined analysis of VEGF and HIF-1a. Final results of the ALICE-2 study
105. MiRNAs modulate gastric cancer drug response by affecting hypoxia signaling
106. Effects of metformin on clinical outcome in advanced hcc patients receiving sorafenib
107. Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD)
108. Possible predictive role of the soluble cd40 ligand (scd40l) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients (pts) treated with first line folfirinox or gemcitabine/nab-paclitaxel combination
109. LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy
110. Impact of age, ECOG PS and type of treatment on progression-free survival and overall survival in second-line therapy for advanced gastric cancer: analysis on 709 cases
111. 2390 LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy
112. 2357 Prognostic factors in 709 advanced gastric cancer patients exposed to second-line therapy
113. P-115 Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity
114. P-147 Outcome of second-line chemotherapy (CT2) after first-line CT (CT1) with platinum plus gemcitabine in advanced biliary tract cancer (aBTC): is it worthwhile?
115. P0365 : Effects of metformin on clinical outcome in advanced HCC patients receiving sorafenib
116. P0323 : LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy
117. P0313 : Correlation between VEGF and VEGF-R polymorphisms, toxicity and clinical outcome in HCC patients receiving sorafenib
118. Correlation of BRAF wild-type status (WT) in primary colorectal tumors with BRAF status in related metastatic sites: Implications for treatment with anti-EGFR antibodies
119. D14 - Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis
120. D5 - Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study
121. D9 - Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
122. D8 - Biliary tract carcinoma and chronic viral hepatitis in Italy: the GICO (Gruppo Italiano COlangiocarcinoma) experience
123. D2 - Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: validation study
124. D7 - Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib
125. 668P - Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram
126. Role of microRNA in response to ionizing radiations: evidences and potential impact on clinical practice for radiotherapy
127. Who Should Receive First-Line Folfirinox? Prognostic Factors in Locally Advanced or Metastatic Pancreatic Cancer Patients
128. Single-Agent or Doublets As Second-Line Chemotherapy After Folfirinox in Patients with Locally Advanced or Metastatic Pancreatic Cancer
129. Clinical Outcome of Elderly (>70Y) Advanced Pancreatic Cancer Patients Receiving Chemotherapy
130. Does First-Line Therapy Affect the Outcome of Patients with Pancreatic Cancer?
131. Angiogenesis Polymorphisms Profile in the Prediction of Clinical Outcome of Advanced Hcc Patients Receiving Sorafenib: Combined Analysis of Vegf and Hif-1. the Alice-2 Study
132. P80 ANGIOGENESIS POLYMORPHISMS PROFILE IN THE PREDICTION OF CLINICAL OUTCOME OF ADVANCED HCC PATIENTS RECEIVING SORAFENIB: COMBINED ANALYSIS OF VEGF AND HIF-1α. THE ALICE-2 STUDY
133. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
134. The role of letrozole (Femara(R)) in breast cancer therapy: A clinical review
135. 708TiP - Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study
136. 443P - Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)
137. B17 - Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)
138. B13 - Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis
139. THU-480 - Multicentric Prospective Study of Validation of Angiogenesis Polymorphisms in HCC Patients Treated with Sorafenib. Innovate Study
140. Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
141. Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
142. Natural History of Bone Metastasis in Gastric Cancer: Results of an Italian Multicenter Survey
143. Body Mass Index and Impaired Fasting Blood Glucose as Predictive Factors of Efficacy in Cetuximab-Based Colorectal Cancer Treatment
144. Synthetic Lethality to Overcome Cancer Drug Resistance
145. mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma
146. Possibile role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results.
147. Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian “bone metastases” survey
148. L33 - LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy
149. L37 - Mast Cells (MCs) Infiltration Affects Pancreatic Cancer (PC) Response To Gemcitabine Based Chemotherapy: In Vitro New Insights
150. L42 - The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.